- Home
- DHR vs PFE Comparison
DHR vs PFE Comparison
Compare DHR & PFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DHR | PFE |
|---|---|---|
| Founded | 1969 | 1849 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.7B | 146.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DHR | PFE |
|---|---|---|
| Price | $217.01 | $27.23 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 16 | 11 |
| Target Price | ★ $250.56 | $27.45 |
| AVG Volume (30 Days) | 4.3M | ★ 54.7M |
| Earning Date | 01-28-2026 | 02-03-2026 |
| Dividend Yield | 0.59% | ★ 6.32% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.05 | 1.36 |
| Revenue | $24,568,000,000.00 | ★ $62,579,000,000.00 |
| Revenue This Year | $5.29 | N/A |
| Revenue Next Year | $5.37 | N/A |
| P/E Ratio | $43.06 | ★ $20.01 |
| Revenue Growth | ★ 2.90 | N/A |
| 52 Week Low | $171.00 | $20.92 |
| 52 Week High | $242.80 | $27.69 |
Technical Indicators
Market Signals| Indicator | DHR | PFE |
|---|---|---|
| Relative Strength Index (RSI) | 39.06 | 57.83 |
| Support Level | $214.94 | $25.26 |
| Resistance Level | $226.03 | $27.19 |
| Average True Range (ATR) | 5.87 | 0.56 |
| MACD | -2.18 | 0.07 |
| Stochastic Oscillator | 10.00 | 75.73 |
Price Performance
Historical ComparisonAbout DHR Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
About PFE Pfizer Inc.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.